Inès Mademan1, Tine Deconinck, Argirios Dinopoulos, Thomas Voit, Ulrike Schara, Koenraad Devriendt, Björn Meijers, Evelyne Lerut, Peter De Jonghe, Jonathan Baets. 1. From the Neurogenetics Group, VIB-Department of Molecular Genetics (I.M., T.D., P.D.J., J.B.), and Laboratory of Neurogenetics, Institute Born-Bunge (I.M., T.D., P.D.J., J.B.), University of Antwerp, Antwerpen, Belgium; University of Athens (A.D.); Attiko University Hospital (A.D.), Athens, Greece; Institute of Myology (T.V.), Paris, France; Department of Pediatric Neurology (U.S.), University of Essen, Essen, Germany; Centre for Human Genetics (K.D.), Department of Nephrology and Renal Transplantation (B.M.), and Pathology (E.L.), University Hospitals Leuven, Leuven, Belgium; Department of Imaging and Pathology (E.L.), KU Leuven, Leuven, Belgium; and Department of Neurology (P.D.J., J.B.), Antwerp University Hospital, Antwerpen, Belgium.
Abstract
OBJECTIVE: Identification of mutations in the inverted formin-2 (INF2) gene in patients with Charcot-Marie-Tooth (CMT) disease combined with focal segmental glomerulosclerosis (FSGS) in order to expand the genetic and phenotypic spectrum. METHODS: We sequenced INF2 in 5 patients with CMT disease and FSGS. Mutations were subsequently screened in family members of the index patient and 264 control individuals. RESULTS: In 3 patients, we detected 2 novel de novo INF2 mutations (p.Leu77Arg and p.Leu69_Ser72del) and a third, most likely de novo mutation (p.Gly114Asp). One of our patients displayed intellectual disability, a phenotypic characteristic not previously associated with INF2. The same patient also showed a more pronounced sensorineural hearing loss than described before. CONCLUSIONS: In exon 2 of INF2, we identified 3 novel mutations that likely affect the protein structure and function. Our findings expand the genetic spectrum of INF2-associated disorders and broaden the associated phenotype with the co-occurrence of intellectual disability and more severe hearing loss than previously reported. De novo INF2 mutations may be more common in patients with CMT disease and FSGS in comparison to FSGS alone. Furthermore, renal dysfunction is more severe and starts earlier in life when associated with CMT disease. Our study confirms that INF2 mutations are a major cause of disease in patients with CMT disease and early signs of nephropathy. Diagnostic screening of INF2 is strongly recommended in isolated patients presenting with CMT disease and FSGS.
OBJECTIVE: Identification of mutations in the inverted formin-2 (INF2) gene in patients with Charcot-Marie-Tooth (CMT) disease combined with focal segmental glomerulosclerosis (FSGS) in order to expand the genetic and phenotypic spectrum. METHODS: We sequenced INF2 in 5 patients with CMT disease and FSGS. Mutations were subsequently screened in family members of the index patient and 264 control individuals. RESULTS: In 3 patients, we detected 2 novel de novo INF2 mutations (p.Leu77Arg and p.Leu69_Ser72del) and a third, most likely de novo mutation (p.Gly114Asp). One of our patients displayed intellectual disability, a phenotypic characteristic not previously associated with INF2. The same patient also showed a more pronounced sensorineural hearing loss than described before. CONCLUSIONS: In exon 2 of INF2, we identified 3 novel mutations that likely affect the protein structure and function. Our findings expand the genetic spectrum of INF2-associated disorders and broaden the associated phenotype with the co-occurrence of intellectual disability and more severe hearing loss than previously reported. De novo INF2 mutations may be more common in patients with CMT disease and FSGS in comparison to FSGS alone. Furthermore, renal dysfunction is more severe and starts earlier in life when associated with CMT disease. Our study confirms that INF2 mutations are a major cause of disease in patients with CMT disease and early signs of nephropathy. Diagnostic screening of INF2 is strongly recommended in isolated patients presenting with CMT disease and FSGS.
Authors: Balajikarthick Subramanian; Justin Chun; Chandra Perez-Gill; Paul Yan; Isaac E Stillman; Henry N Higgs; Seth L Alper; Johannes S Schlöndorff; Martin R Pollak Journal: J Am Soc Nephrol Date: 2020-01-10 Impact factor: 10.121
Authors: Samet Bayraktar; Julian Nehrig; Ekaterina Menis; Kevser Karli; Annette Janning; Thaddäus Struk; Jan Halbritter; Ulf Michgehl; Michael P Krahn; Christian E Schuberth; Hermann Pavenstädt; Roland Wedlich-Söldner Journal: J Am Soc Nephrol Date: 2020-06 Impact factor: 10.121
Authors: José Berciano; Antonio García; Elena Gallardo; Kristien Peeters; Ana L Pelayo-Negro; Silvia Álvarez-Paradelo; José Gazulla; Miriam Martínez-Tames; Jon Infante; Albena Jordanova Journal: J Neurol Date: 2017-03-31 Impact factor: 4.849
Authors: Rachel C Challis; Troels Ring; Yaobo Xu; Edwin K S Wong; Oliver Flossmann; Ian S D Roberts; Saeed Ahmed; Michael Wetherall; Giedrius Salkus; Vicky Brocklebank; Julian Fester; Lisa Strain; Valerie Wilson; Katrina M Wood; Kevin J Marchbank; Mauro Santibanez-Koref; Timothy H J Goodship; David Kavanagh Journal: J Am Soc Nephrol Date: 2016-12-14 Impact factor: 10.121
Authors: Friederike Werheid; Hamid Azzedine; Eva Zwerenz; Ahmet Bozkurt; Marcus J Moeller; Lilian Lin; Michael Mull; Martin Häusler; Jörg B Schulz; Joachim Weis; Kristl G Claeys Journal: Brain Behav Date: 2016-03-04 Impact factor: 2.708